GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
O

OrbusNeich Medical Group Holdings 6929.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

3.72

+0.54%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About OrbusNeich Medical Group Holdings

Its shares trade on HKEX under the ticker 6929.HK. It has been listed since 23 December 2022. In the fiscal year to 31 December 2025, it reported net income of $328.3m. At that date it held total assets of $3.55bn and shareholders' equity of $3.24bn.

OrbusNeich Medical Group Holdings Ltd. operates as an investment holding company. The company employs 954 full-time employees The company went IPO on 2022-12-23. The firm is engaged in the design, development, manufacture, distribution and sale of interventional medical devices for the treatment of coronary heart disease and peripheral vascular diseases. The firm's main products include percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) balloons. In addition, the Company's products also include semi-compliant balloons and scoring balloons for pre-dilatation and lesion preparation, coronary stents for implantation, non-compliant balloons for post-dilatation and specialty catheters. The firm mainly conducts its businesses in domestic and overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
23 Dec 2022
Employees
954

Leadership

Pay as last reported

  • Mr. David ChienExecutive Chairman of the Board, Chief Executive Officer$355,000
  • Mr. Wing Shing ChenChief Financial Officer, Executive Director, Company Secretary, since 2018$467,000
  • Ms. Kwai Ching LauChief Operating Officer, Executive Director, since 2020$320,000
  • Mr. Robert CottoneChief Technology Officer
  • Mr. Alain KhairChief Commercial Officer
  • Mr. Ting San LeungNon-Executive Director
  • Dr. Yi ZhouNon-Executive Director
  • Mr. Yip Keung ChanNon-Executive Independent Director
  • Mr. Ka Keung LauNon-Executive Independent Director
  • Dr. Lai Fan TamNon-Executive Independent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • The company employs 954 full-time staff members.
  • It designs and manufactures interventional medical devices.
  • Products include coronary stents and various balloons.

Weaknesses

  • The city of operation is listed as unknown.
  • Specific financial metrics are not provided in the text.
  • The source description is explicitly treated as untrusted.

Opportunities

  • The firm conducts business in domestic markets.
  • Overseas markets are also part of its business scope.
  • Products treat coronary heart disease and peripheral vascular diseases.

Threats

  • The source description is treated as untrusted facts.
  • Instructions inside the source description must not be followed.
  • No specific competitor data is available in the text.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.